1. Home
  2. EDD vs ARMP Comparison

EDD vs ARMP Comparison

Compare EDD & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Morgan Stanley Emerging Markets Domestic Debt Fund Inc.

EDD

Morgan Stanley Emerging Markets Domestic Debt Fund Inc.

HOLD

Current Price

$5.45

Market Cap

397.7M

Sector

Finance

ML Signal

HOLD

ARMP

Armata Pharmaceuticals Inc.

HOLD

Current Price

$12.28

Market Cap

383.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EDD
ARMP
Founded
2007
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
397.7M
383.7M
IPO Year
N/A
1996

Fundamental Metrics

Financial Performance
Metric
EDD
ARMP
Price
$5.45
$12.28
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$15.00
AVG Volume (30 Days)
498.1K
33.4K
Earning Date
01-01-0001
05-13-2026
Dividend Yield
7.52%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.39
$0.90
52 Week High
$6.18
$13.75

Technical Indicators

Market Signals
Indicator
EDD
ARMP
Relative Strength Index (RSI) 50.55 66.63
Support Level $5.44 $5.14
Resistance Level $5.68 $13.75
Average True Range (ATR) 0.13 1.11
MACD 0.02 0.31
Stochastic Oscillator 82.47 94.89

Price Performance

Historical Comparison
EDD
ARMP

About EDD Morgan Stanley Emerging Markets Domestic Debt Fund Inc.

Morgan Stanley Emerging Markets Domestic Debt Fund Inc is a closed-end management investment company. The company's primary investment objective is to seek a high level of current income, with a secondary investment objective of long-term capital appreciation. It seeks to achieve investment objectives by investing, under normal circumstances, at least 80% of its managed assets in emerging markets domestic debt. The fund's portfolio includes sovereign, quasi-sovereign, corporate bonds in emerging markets.

About ARMP Armata Pharmaceuticals Inc.

Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.

Share on Social Networks: